Clinical Study in the Treatment of Patients With COVID-19
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase
III study.
The study is designed for 2 treatment groups:
- Group 1 of the investigational drug - Patients receive standard therapy and the
investigational drug.
- Group 2 of comparison - Patients receive standard therapy and placebo.